Versant Ventures related stories
All articles and analysis
Versant to raise $250M fifth fundVersant Ventures has filed with the Securities and Exchange Commission to raise a $250 million fifth fund. The fund's first close has yet to occur. Versant Venture Capital V will be run by managing directors Robin Praeger, Bradley Bolzon, Samuel Colella, Ross Jaffe, William Link, Kirk Nielsen and Charles Warden, according to the filing dated Oct. 18.
VCs on the Move, August 2013VMware Exec Joins Greylock as Partner: Greylock Partners announced on its blog in June that Jerry Chen, formerly with VMware, has joined Greylock Partners as partner.
- Audentes Therapeutics Nets $30 Mln in Series A Financing
Audentes Therapeutics said Thursday that it has secured $30 million in Series A financing. The lead investor was OrbiMed Advisors. Versant Ventures and 5AM Ventures also participated in the round. Also, Jonathan Silverstein of OrbiMed Advisors, has been named chairman of Audentes' board. Headquartered in San Francisco, Calif., Audentes Therapeutics is a biotechnology company.
- Versant Ventures Names New Operating Partner
Newport, California-based Versant Ventures said Friday that it has named James V. Mazzo as an operating partner. In his new position, Mazzo will focus on patient needs, new technology advancements and investment opportunities in the healthcare sector. He will also serve as chairman and CEO of AcuFocus, a Versant portfolio company. Previously, Mazzo was the CEO of Advanced Medical Optics and senior vice president of Abbott Labs.
- Maroney Joins ForSight VISION5 as President, CEO
John F. Maroney is joining ForSight VISION5 as President, CEO and Director. ForSight VISION5 also completed its Series B-1 financing which raised $9.3m and was led by Technology Partners and joined by Delphi Ventures. VISION5, a clinical development stage company focused on ophthalmic diseases, is the fifth company created by ForSight Labs. Maroney will continue to serve as a Venture Partner for Delphi Ventures.
- GlaxoSmithKline Buys Okairos for Approx. $325 Mln
GlaxoSmithKline, the global healthcare company, said on Wednesday that it has acquired Okairos AG, a Swiss-based developer of vaccine platform technologies for €250 million (approximately $325 million) in cash. The transaction will also include some early stage assets. Prior to the acquisition, Okairos was backed by the following life science VC firms: BioMedInvest, the Boehringer Ingelheim Venture Fund, LSP, Novartis Venture Funds and Versant Ventures.
- GenSight Biologics Adds $41.6M Series A
GenSight Biologics, a company focused on the development of ophthalmic therapeutics using gene therapy, has closed a 32 million euro ($41.6 million) Series A round. Novartis Venture Fund, Abingworth LLP, Versant Ventures and Index Ventures co-led the round. GenSight is based in Paris, on the campus of the Vision Institute.
- Novira Therapeutics Completes Series A Financing
Novira Therapeutics has completed a Series A financing after securing $7.5 million from new investor Versant Ventures. This brings the total raised from all investors in the round to $25 million. Versant joins 5AM Ventures and Canaan Partners, which led the first closing of the Series A in August 2012.
- Theraclone Sciences Closes Another $14 Mln in Financing
Theraclone Sciences said Monday it closed $14 million in additional financing. Existing investors -- ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo -- committed $8 million equity. Another $6 million in venture debt was secured through a credit facility with MidCap Financial and Silicon Valley Bank. Seattle-based Theraclone develops novel therapeutic antibodies for the treatment of infectious disease and cancer.
- Holaira Closes $10M Series C
Holaira Inc., formerly known as Innovative Pulmonary Solutions Inc., has closed on $10 million in Series C financing. Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, and Versant Ventures participated in the round. The company makes medical devices to treat obstructive lung diseases.